Cannara Biotech (LOVE) Q4 2024 earnings summary

Executive summary

• Achieved record annual revenues up to $82.2M in FY2024, with 14 consecutive quarters of positive Adjusted EBITDA and $6.4M net income, ranking 8th in Canada by sales and 3rd in Quebec, with three flagship brands and a production run rate of 33,500kg as of August 2024.

• National market share reached up to 3.8% in October 2024, with leading positions in infused pre-rolls, live resin vape carts, hash rosin, and CBD flower; Quebec market share was as high as 12.6%.

• Operates two large-scale Quebec cultivation facilities with 250,000 sq. ft. of active growing capacity and ongoing capital investments.

• Achieved $10.7M in positive operating cash flow for FY2024, with free cash flow of $3.2M.

• Expects existing cash, forecasted cash flows, and undrawn credit facilities to fund operations for at least 12 months.

Financial highlights

• FY2024 net revenues (after excise taxes) were up to $81.7M, with gross profit before fair value adjustments of $27.9M and a gross margin of 34%.

• Adjusted EBITDA for FY2024 was $15.1M, net income was $6.4M, and free cash flow was $3.2M.

• Total revenue, including lease and service revenues, reached $82.1M.

• Operating income for 2024 was $10.1M, down from $11.9M in 2023 due to higher marketing/admin expenses.

• Cash on hand at year-end was $6.6M, with working capital of $40.5M.

Outlook and guidance

• Plans to scale annualized production capacity to 100,000kg at existing facilities and activate two additional Valleyfield grow zones in 2025, adding 50,000 sq. ft. of canopy.

• Over 20 new products planned for launch in 2025, focusing on high-volume categories and innovative formats.

• Focus remains on maintaining strong operating margins and delivering premium products at accessible prices.

• Management expects continued funding of operations through sales, cash, and available credit, with a focus on product pipeline and operational efficiency.